Why the study?
The study was conducted to determine the effects of mitoquinone alone and combined with moderate endurance training on blood pressure, cardiac function, total oxidant status, and serum miR-145, miR-133a, and hs-CRP levels in male patients with hypertension.
Does mitoquinone alone or combined with moderate endurance training improve blood pressure, cardiac function, oxidative stress, inflammation, and circulating miR-133a and miR-145 levels in male patients with moderate hypertension?
Does mitoquinone alone or combined with moderate endurance training improve blood pressure, cardiac function, oxidative stress, inflammation, and circulating miR-133a and miR-145 levels in male patients with moderate hypertension?
Combining the mitochondria-targeted antioxidant mitoquinone with moderate endurance training for 6 weeks significantly lowers blood pressure, left ventricular hypertrophy, and left atrial filling pressure in men with moderate hypertension, alongside improvements in oxidative stress, inflammation, and cardioprotective microRNAs.
Answers are grounded in this paper and cite their sources.
Should not yet change practice; hypothesis-generating for MitoQ with endurance training in moderate hypertension.
We used mitoquinone (MitoQ), a mitochondria-targeted antioxidant, alone and combined with moderate ET (endurance training) in male patients with hypertension to determine their effects on blood pressure (BP), cardiac function, TOS (total oxidant status), and serum miR-145, miR-133a, and hs-CRP levels. Moderately HTN patients participated in groups of Placebo, MitoQ, ET, and MitoQ+ET. Serum was used to assess miR-133a, miR-145, TOS, and hs-CRP, and echocardiography was performed to assess cardiac performance. In the MitoQ+ET group, BP, left ventricular hypertrophy, and cardiac filling pressure decreased. Ejection fraction did not change significantly. Both MitoQ+ET and ET significantly reduced TOS and hs-CRP and significantly increased miR-145 and miR-133a in serum. Overall anti-inflammatory and antioxidant properties of ET and MitoQ were associated with miR-145 and miR-133a increase, and with cardiac function and BP improvements in patients with HTN. MitoQ+ET may potentially be used as an alternative therapy in HTN treatment.
No takes yet. Share an insight, caveat, or question.
Masoumi‐Ardakani et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: